AstraZeneca PLC (AZN.L)
| Previous close | 12,060.00 |
| Open | 12,116.00 |
| Bid | 12,182.00 x 0 |
| Ask | 12,186.00 x 0 |
| Day's range | 12,108.00 - 12,332.00 |
| 52-week range | 9,461.00 - 12,704.00 |
| Volume | |
| Avg. volume | 1,890,216 |
| Market cap | 188.823B |
| Beta (5Y monthly) | 0.15 |
| PE ratio (TTM) | 38.06 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 2.34 (1.92%) |
| Ex-dividend date | 08 Aug 2024 |
| 1y target est | N/A |
- Business Wire
AstraZeneca’s H1 and Q2 2024 Financial Results
CAMBRIDGE, United Kingdom, July 25, 2024--H1/Q2 2024 Earnings Release (25 July 2024)
- Business Wire
IMFINZI® (durvalumab) demonstrated statistically significant and clinically meaningful improvement in event-free survival and overall survival for muscle-invasive bladder cancer in NIAGARA Phase III trial
WILMINGTON, Del., June 25, 2024--Positive high-level results from the NIAGARA Phase III trial showed AstraZeneca’s IMFINZI® (durvalumab) in combination with chemotherapy demonstrated a statistically significant and clinically meaningful improvement in the primary endpoint of event-free survival (EFS) and the key secondary endpoint of overall survival (OS) versus neoadjuvant chemotherapy for patients with muscle-invasive bladder cancer (MIBC). Patients were treated with IMFINZI in combination wit
- Business Wire
IMFINZI® (durvalumab) plus chemotherapy approved in the US for mismatch repair deficient advanced or recurrent endometrial cancer
WILMINGTON, Del., June 17, 2024--AstraZeneca’s IMFINZI® (durvalumab) in combination with carboplatin and paclitaxel followed by IMFINZI monotherapy has been approved in the US as treatment for adult patients with primary advanced or recurrent endometrial cancer that is mismatch repair deficient (dMMR).1
